Machine Learning–Based Brain Age Modeling Reveals Accelerated Structural Degeneration in Parkinson’s Disease
Objective: To compare the rate of global brain structural degeneration between healthy controls (HC) and patients with Parkinson’s disease (PD). Background: Normal aging is accompanied…Parkinsonism in B-Cell Maturation Antigen-Targeting CAR-T Cell Cancer Therapies
Objective: Describe parkinsonism after B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for treatment of multiple myeloma. Background: BCMA-targeted CART-cell therapy effectively treats…Phenoconversion from Rapid Eye Movement Sleep Behavior Disorder to Parkinson’s Disease: A multimodal Imaging Study
Objective: To elucidate the pathological progression from rapid eye movement sleep behavior disorder (RBD) to Parkinson’s disease (PD), we investigated tissue-level neurodegenerative changes using multimodal…Olfactory Function as a Biomarker of Disease Progression in Progressive Supranuclear Palsy
Objective: To investigate whether olfactory function predicts disease progression in progressive supranuclear palsy (PSP). Background: Olfactory function is under-investigated in PSP. Emerging evidence from clinico-neuropathological…Targeting c-Abl/Drp1-Dependent Mitochondrial Fission: Neuroprotective Effects of Berberine Chloride in Parkinson’s Disease Models
Objective: To investigate the neuroprotective potential of berberine chloride in Parkinson’s disease (PD) by modulating pathological mitochondrial fission through c-Abl–mediated Drp1 phosphorylation using integrated bioinformatics,…The Impact of Insurance on Delivery of Huntington’s Care at an HDSA Center of Excellence
Objective: To determine the association between health insurance and Huntington’s Disease (HD) time to diagnosis, delays in access to specialty care, and HD specific clinical…Longitudinal cognitive trajectories and predictors of dementia conversion in Parkinson’s disease
Objective: To determine clinical predictors of longitudinal cognitive decline and dementia conversion in a real-world Parkinson’s disease (PD) cohort. Background: Cognitive impairment is one of…Parkinson’s Disease Early Diagnostic and Prognostic Biomarkers Identified by Large-scale Plasma and Cerebrospinal Fluid Proteomic Profiling
Objective: To identify reliable diagnostic and prognostic protein biomarkers for early-stage Parkinson’s disease (PD) using large-scale proteomic profiling of plasma and cerebrospinal fluid (CSF).To identify…Axial parkinsonism after 15 years of pallidal stimulation in generalized dystonia
Objective: To characterize long-term motor outcomes and emergence of parkinsonian symptoms after 15 years of bilateral globus pallidus internus deep brain stimulation (GPi-DBS) in isolated…The Emerging Landscape of Genotype-Stratified Clinical Trials in Parkinson’s Disease and Atypical Parkinsonian Disorders
Objective: To characterize the landscape of genotype-stratified clinical trials in Parkinson’s disease (PD) and atypical parkinsonian disorders (APD), including therapeutic targets, geographic representation, and trial…
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 1942
- Next Page »